Back to Search Start Over

Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway.

Authors :
Simpson DS
Pang J
Weir A
Kong IY
Fritsch M
Rashidi M
Cooney JP
Davidson KC
Speir M
Djajawi TM
Hughes S
Mackiewicz L
Dayton M
Anderton H
Doerflinger M
Deng Y
Huang AS
Conos SA
Tye H
Chow SH
Rahman A
Norton RS
Naderer T
Nicholson SE
Burgio G
Man SM
Groom JR
Herold MJ
Hawkins ED
Lawlor KE
Strasser A
Silke J
Pellegrini M
Kashkar H
Feltham R
Vince JE
Source :
Immunity [Immunity] 2022 Mar 08; Vol. 55 (3), pp. 423-441.e9. Date of Electronic Publication: 2022 Feb 08.
Publication Year :
2022

Abstract

Cell death plays an important role during pathogen infections. Here, we report that interferon-γ (IFNγ) sensitizes macrophages to Toll-like receptor (TLR)-induced death that requires macrophage-intrinsic death ligands and caspase-8 enzymatic activity, which trigger the mitochondrial apoptotic effectors, BAX and BAK. The pro-apoptotic caspase-8 substrate BID was dispensable for BAX and BAK activation. Instead, caspase-8 reduced pro-survival BCL-2 transcription and increased inducible nitric oxide synthase (iNOS), thus facilitating BAX and BAK signaling. IFNγ-primed, TLR-induced macrophage killing required iNOS, which licensed apoptotic caspase-8 activity and reduced the BAX and BAK inhibitors, A1 and MCL-1. The deletion of iNOS or caspase-8 limited SARS-CoV-2-induced disease in mice, while caspase-8 caused lethality independent of iNOS in a model of hemophagocytic lymphohistiocytosis. These findings reveal that iNOS selectively licenses programmed cell death, which may explain how nitric oxide impacts disease severity in SARS-CoV-2 infection and other iNOS-associated inflammatory conditions.<br />Competing Interests: Declaration of interests The authors declare that D.S.S., J.P., A.W., I.Y.K., M.R., J.P.C., K.C.D., S.H., H.A., M.D., Y.D., L.M., M.D., A.S.H., S.E.N., J.R.G., M.J.H., E.D.H., A.S., J.S., M.P., R.F., and J.E.V. are employees or former employees of the Walter and Eliza Hall Medical Institute, which receives milestone payments from Genentech and AbbVie for the development of ABT-199 for cancer therapy. J.E.V. sits on the advisory board of Avammune Therapeutics.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-4180
Volume :
55
Issue :
3
Database :
MEDLINE
Journal :
Immunity
Publication Type :
Academic Journal
Accession number :
35139355
Full Text :
https://doi.org/10.1016/j.immuni.2022.01.003